Diagnostic values of osteopontin combined with CA125 for ovarian cancer: a meta-analysis.

Abstract

Osteopontin (OPN) is currently one of the most studied serum biomarkers of ovarian cancer (OC). This meta-analysis aims to ascertain whether OPN is a useful diagnostic biomarker for OC and determine the overall diagnostic accuracy of OPN measurement when combined with cancer antigen 125 (CA125). A systematic literature search was conducted in Cochrane Library, PubMed, EMBASE, CBM, and China National Knowledge Infrastructure databases. Information was independently extracted by two investigators. The Quality Assessment for Studies of Diagnostic Accuracy tool was applied to examine the quality of eligible studies, and a bivariate model was used to calculate the pooled estimates. We identified 17 and 10 studies that evaluated the role of OPN alone and OPN combined with CA125 in diagnosing ovarian tumor, respectively. The overall diagnostic sensitivity and specificity of OPN in OC were 0.766 (95% CI 0.685-0.831) and 0.897 (95% CI 0.849-0.931), correspondingly. When OPN was combined with CA125, the sensitivity and specificity were 0.871 (95% CI 0.788-0.924) and 0.881 (95% CI 0.837-0.914), respectively. OPN is a useful tumor biomarker in future screening tests of OC and can be a promising adjunct to CA125. Additional studies with multicenter trials and carefully selected controls are needed to further verify the results.